|
1)Verbeek RE, Leenders M, Ten Kate FJ, et al. Surveillance of Barrettʼs esophagus and mortality from esophageal adenocarcinoma: a population-based cohort study. Am J Gastroenterol. 2014; 109: 1215-22
|
|
|
|
2)Bhat SK, McManus DT, Coleman HG, et al. Oesophageal adenocarcinoma and prior diagnosis of Barrettʼs oesophagus: a population-based study. Gut. 2014 Apr 3. [Epub ahead of print]
|
|
|
|
|
|
3)Khandwalla HE, Graham DY, Kramer JR, et al. Barrettʼs esophagus suspected at endoscopy but no specialized intestinal metaplasia on biopsy, whatʼs next? Am J Gastroenterol. 2014; 109: 178-82
|
|
|
|
|
|
4)Singh S, Manickam P, Amin AV, et al. Incidence of esophageal adenocarcinoma in Barrettʼs esophagus with low-grade dysplasia: a systematic review and meta-analysis. Gastrointest Endosc. 2014; 79: 897-909. e4; quiz 983 e1, 983. e3
|
|
|
|
|
|
5)Kastelein F, van Olphen S, Steyerberg EW, et al. Surveillance in patients with long-segment Barrettʼs oesophagus: a cost-effectiveness analysis. Gut. 2014 Jul 18. [Epub ahead of print]
|
|
|
|
|
|
6)Giacchino M, Bansal A, Kim RE, et al. Clinical utility and interobserver agreement of autofluorescence imaging and magnification narrow-band imaging for the evaluation of Barrettʼs esophagus: a prospective tandem study. Gastrointest Endosc. 2013; 77: 711-8
|
|
|
|
|
|
7)Sharma P, Hawes RH, Bansal A, et al. Standard endoscopy with random biopsies versus narrow band imaging targeted biopsies in Barrettʼs oesophagus: a prospective, international, randomised controlled trial. Gut. 2013; 62: 15-21
|
|
|
|
|
|
8)Qumseya BJ, Wang H, Badie N, et al. Advanced imaging technologies increase detection of dysplasia and neoplasia in patients with Barrettʼs esophagus: a meta-analysis and systematic review. Clin Gastroenterol Hepatol. 2013; 11: 1562-70. e1-2
|
|
|
|
|
|
9)Longcroft-Wheaton G, Brown J, Basford P, et al. Duration of acetowhitening as a novel objective tool for diagnosing high risk neoplasia in Barrettʼs esophagus: a prospective cohort trial. Endoscopy. 2013; 45: 426-32
|
|
|
|
|
|
10)Tholoor S, Bhattacharyya R, Tsagkournis O, et al. Acetic acid chromoendoscopy in Barrettʼs esophagus surveillance is superior to the standardized random biopsy protocol: results from a large cohort study (with video). Gastrointest Endosc. 2014; 80: 417-24
|
|
|
|
|
|
11)Almond LM, Hutchings J, Lloyd G, et al. Endoscopic Raman spectroscopy enables objective diagnosis of dysplasia in Barrettʼs esophagus. Gastrointest Endosc. 2014; 79: 37-45
|
|
|
|
|
|
12)Suter MJ, Gora MJ, Lauwers GY, et al. Esophageal-guided biopsy with volumetric laser endomicroscopy and laser cautery marking: a pilot clinical study. Gastrointest Endosc. 2014; 79: 886-96
|
|
|
|
|
|
13)Canto MI, Anandasabapathy S, Brugge W, et al. In vivo endomicroscopy improves detection of Barrettʼs esophagus-related neoplasia: a multicenter international randomized controlled trial (with video). Gastrointest Endosc. 2014; 79: 211-21
|
|
|
|
|
|
14)Boerwinkel DF, Holz JA, Kara MA, et al. Effects of autofluorescence imaging on detection and treatment of early neoplasia in patients with Barrettʼs esophagus. Clin Gastroenterol Hepatol. 2014; 12: 774-81
|
|
|
|
|
|
15)Enestvedt BK, Lugo R, Guarner-Argente C, et al. Location, location, location: does early cancer in Barrettʼs esophagus have a preference? Gastrointest Endosc. 2013; 78: 462-7
|
|
|
|
|
|
16)Cassani L, Sumner E, Slaughter JC, et al. Directional distribution of neoplasia in Barrettʼs esophagus is not influenced by distance from the gastroesophageal junction. Gastrointest Endosc. 2013; 77: 877-82
|
|
|
|
|
|
17)Gaddam S, Singh M, Balasubramanian G, et al. Persistence of nondysplastic Barrettʼs esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort. Gastroenterology. 2013; 145: 548-53. e1
|
|
|
|
|
|
18)Gordon LG, Mayne GC, Hirst NG, et al. Cost-effectiveness of endoscopic surveillance of non-dysplastic Barrettʼs esophagus. Gastrointest Endosc. 2014; 79: 242-56. e6
|
|
|
|
|
|
19)Pohl H, Wrobel K, Bojarski C, et al. Risk factors in the development of esophageal adenocarcinoma. Am J Gastroenterol. 2013; 108: 200-7
|
|
|
|
|
|
20)Coleman HG, Bhat SK, Murray LJ, et al. Symptoms and endoscopic features at barrettʼs esophagus diagnosis: implications for neoplastic progression risk. Am J Gastroenterol. 2014; 109: 527-34
|
|
|
|
|
|
21)Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrettʼs oesophagus. Gut. 2014; 63: 7-42
|
|
|
|
|
|
22)Singh S, Sharma AN, Murad MH, et al. Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013; 11: 1399-412. e7
|
|
|
|
|
|
23)Duggan C, Onstad L, Hardikar S, et al. Association between markers of obesity and progression from Barrettʼs esophagus to esophageal adenocarcinoma. Clin Gastroenterol Hepatol. 2013; 11: 934-43
|
|
|
|
|
|
24)Fischbach LA, Graham DY, Kramer JR, et al. Association between Helicobacter pylori and Barrettʼs esophagus: a case-control study. Am J Gastroenterol. 2014; 109: 357-68
|
|
|
|
|
|
25)Rubenstein JH, Inadomi JM, Scheiman J, et al. Association between Helicobacter pylori and Barrettʼs esophagus, erosive esophagitis, and gastroesophageal reflux symptoms. Clin Gastroenterol Hepatol. 2014; 12: 239-45
|
|
|
|
|
|
26)Wu J, Pan YM, Wang TT, et al. Endotherapy versus surgery for early neoplasia in Barrettʼs esophagus: a meta-analysis. Gastrointest Endosc. 2014; 79: 233-41. e2
|
|
|
|
|
|
27)Konda VJ, Gonzalez Haba Ruiz M, Koons A, et al. Complete Endoscopic Mucosal Resection Is Effective and Durable Treatment for Barrettʼs-Associated Neoplasia. Clin Gastroenterol Hepatol. 2014 Apr 13. [Epub ahead of print]
|
|
|
|
|
|
28)Pech O, May A, Manner H, et al. Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. Gastroenterology. 2014; 146: 652-60. e1
|
|
|
|
|
|
29)Saligram S, Chennat J, Hu H, et al. Endotherapy for superficial adenocarcinoma of the esophagus: an American experience. Gastrointest Endosc. 2013; 77: 872-6
|
|
|
|
|
|
30)Tomizawa Y, Iyer PG, Wong Kee Song LM, et al. Safety of endoscopic mucosal resection for Barrettʼs esophagus. Am J Gastroenterol. 2013; 108: 1440-7; quiz 1448
|
|
|
|
|
|
31)Kagemoto K, Oka S, Tanaka S, et al. Clinical outcomes of endoscopic submucosal dissection for superficial Barrettʼs adenocarcinoma. Gastrointest Endosc. 2014; 80: 239-45
|
|
|
|
|
|
32)Bulsiewicz WJ, Kim HP, Dellon ES, et al. Safety and efficacy of endoscopic mucosal therapy with radiofrequency ablation for patients with neoplastic Barrettʼs esophagus. Clin Gastroenterol Hepatol. 2013; 11: 636-42
|
|
|
|
|
|
33)Dulai PS, Pohl H, Levenick JM, et al. Radiofrequency ablation for long- and ultralong-segment Barrettʼs esophagus: a comparative long-term follow-up study. Gastrointest Endosc. 2013; 77: 534-41
|
|
|
|
|
|
34)Haidry RJ, Dunn JM, Butt MA, et al. Radiofrequency ablation and endoscopic mucosal resection for dysplastic barrettʼs esophagus and early esophageal adenocarcinoma: outcomes of the UK National Halo RFA Registry. Gastroenterology. 2013; 145: 87-95
|
|
|
|
|
|
35)Orman ES, Li N, Shaheen NJ. Efficacy and durability of radiofrequency ablation for Barrettʼs Esophagus: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013; 11: 1245-55
|
|
|
|
|
|
36)Chadwick G, Groene O, Markar SR, et al. Systematic review comparing radiofrequency ablation and complete endoscopic resection in treating dysplastic Barrettʼs esophagus: a critical assessment of histologic outcomes and adverse events. Gastrointest Endosc. 2014; 79: 718-31. e3
|
|
|
|
|
|
37)Gupta M, Iyer PG, Lutzke L, et al. Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrettʼs esophagus: results from a US Multicenter Consortium. Gastroenterology. 2013; 145: 79-86. e1
|
|
|
|
|
|
38)Anders M, Bahr C, El-Masry MA, et al. Long-term recurrence of neoplasia and Barrettʼs epithelium after complete endoscopic resection. Gut. 2014; 63: 1535-43
|
|
|
|
|
|
39)Orman ES, Kim HP, Bulsiewicz WJ, et al. Intestinal metaplasia recurs infrequently in patients successfully treated for Barrettʼs esophagus with radiofrequency ablation. Am J Gastroenterol. 2013; 108: 187-95; quiz 196
|
|
|
|
|
|
40)Pasricha S, Bulsiewicz WJ, Hathorn KE, et al. Durability and Predictors of Successful Radiofrequency Ablation for Barrettʼs Esophagus. Clin Gastroenterol Hepatol. 2014 May 9. [Epub ahead of print]
|
|
|
|
|
|
41)Lee JK, Cameron RG, Binmoeller KF, et al. Recurrence of subsquamous dysplasia and carcinoma after successful endoscopic and radiofrequency ablation therapy for dysplastic Barrettʼs esophagus. Endoscopy. 2013; 45: 571-4
|
|
|
|
|
|
42)Mitlyng B, Ganz R. Development of subsquamous high-grade dysplasia and adenocarcinoma after successful radiofrequency ablation of Barrettʼs esophagus. Gastroenterology. 2013; 144: e17
|
|
|
|
|
|
43)Gosain S, Mercer K, Twaddell WS, et al. Liquid nitrogen spray cryotherapy in Barrettʼs esophagus with high-grade dysplasia: long-term results. Gastrointest Endosc. 2013; 78: 260-5
|
|
|
|
|
|
44)Singh S, Garg SK, Singh PP, et al. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrettʼs oesophagus: a systematic review and meta-analysis. Gut. 2014; 63: 1229-37
|
|
|
|
|
|
45)Abnet CC, Freedman ND, Kamangar F, et al. Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. Br J Cancer. 2009; 100: 551-7
|
|
|
|
|
|
46)Khalaf N, Nguyen T, Ramsey D, et al. Nonsteroidal Anti-inflammatory Drugs and the Risk of Barrettʼs Esophagus. Clin Gastroenterol Hepatol. 2014 Apr 30. [Epub ahead of print]
|
|
|
|
|
|
47)Nguyen T, Khalaf N, Ramsey D, et al. Statin use is associated with a decreased risk of Barrettʼs esophagus. Gastroenterology. 2014; 147: 314-23
|
|
|
|
|
|
48)Singh S, Singh AG, Singh PP, et al. Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrettʼs esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013; 11: 620-9
|
|
|
|
|
|
49)Cook MB, Wood SN, Cash BD, et al. Association Between Circulating Levels of Sex Steroid Hormones and Barrettʼs Esophagus in Men: A Case-Control Analysis. Clin Gastroenterol Hepatol. 2014 Aug 24. [Epub ahead of print]
|
|
|
|
|
|
50)Rajendra S, Wang B, Snow ET, et al. Transcriptionally active human papillomavirus is strongly associated with Barrettʼs dysplasia and esophageal adenocarcinoma. Am J Gastroenterol. 2013; 108: 1082-93
|
|
|
|
|
|
51)Matsuzaki J, Suzuki H. MicroRNAs in Barrettʼs esophagus: future prospects. Front Genet. 2014; 5: 69
|
|
|
|
|
|
52)van Baal JW, Verbeek RE, Bus P, et al. microRNA-145 in Barrettʼs oesophagus: regulating BMP4 signalling via GATA6. Gut. 2013; 62: 664-75
|
|
|
|
|
|
53)Matsuzaki J, Suzuki H, Tsugawa H, et al. Bile acids increase levels of microRNAs 221 and 222, leading to degradation of CDX2 during esophageal carcinogenesis. Gastroenterology. 2013; 145: 1300-11
|
|
|
|
|
|
54)Wu W, Bhagat TD, Yang X, et al. Hypomethylation of noncoding DNA regions and overexpression of the long noncoding RNA, AFAP1-AS1, in Barrettʼs esophagus and esophageal adenocarcinoma. Gastroenterology. 2013; 144: 956-66. e4
|
|
|
|
|